<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408523</url>
  </required_header>
  <id_info>
    <org_study_id>SP0982</org_study_id>
    <nct_id>NCT02408523</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications</brief_title>
  <acronym>VALOR</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB BIOSCIENCES, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating efficacy &amp; safety of lacosamide versus Placebo in a blinded fashion as add-on
      Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject ≥ 4 years of age
      with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum
      duration of study drug administration is 28 weeks. Eligible subjects may choose to enter the
      open-label extension study after completion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to the second primary generalized tonic clonic (PGTC) seizure during the 24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</measure>
    <time_frame>24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom for primary generalized tonic clonic (PGTC) seizures during the 24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</measure>
    <time_frame>24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in primary generalized tonic clonic (PGTC) seizure frequency per 28 days from the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) to the first 6 weeks of the Treatment Period</measure>
    <time_frame>From the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) to the first 6 weeks of the Treatment Period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent change in primary generalized tonic clonic (PGTC) seizure frequency per 28 days from the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) to the 24-week Treatment Period</measure>
    <time_frame>From the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) to the 24-week Treatment Period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first primary generalized tonic clonic (PGTC) seizure 24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</measure>
    <time_frame>24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Lacosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacosamide 50 mg tablets (Starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for subjects ≥ 50 kg).
Lacosamide oral solution 10 mg/ml (Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for subjects &lt; 30 kg).
Lasosamide oral solution 10 mg/ml Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for subjects ≥ 30 kg to &lt; 50 kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 50 mg tablets (Starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for subjects ≥ 50 kg).
Placebo oral solution 10 mg/ml (Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for subjects &lt; 30 kg).
Placebo oral solution 10 mg/ml Starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for subjects ≥ 30 kg to &lt; 50 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide Tablet</intervention_name>
    <description>Active Substance: Lacosamide
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use</description>
    <arm_group_label>Lacosamide</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasosamide Oral Solution</intervention_name>
    <description>Active Substance: Lacosamide
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use</description>
    <arm_group_label>Lacosamide</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Tablet</intervention_name>
    <description>Active Substance: Placebo
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral Solution</intervention_name>
    <description>Active Substance: Placebo
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with a confirmed diagnosis at least 24 weeks prior to Visit 1 and a disease
             onset prior to 30 years of age, consistent with idiopathic generalized epilepsy (IGE)
             experiencing primary generalized tonic-clonic (PGTC) seizures (Type IIE) that are
             classifiable according to the International League Against Epilepsy (ILAE)
             Classification of Epileptic Seizures (ILAE, 1981)

          -  Subject has ≥ 3 PGTC seizures during the 16-week Combined Baseline (12-week
             Historical Baseline plus 4-week Prospective Baseline)

          -  If a brain magnetic resonance imaging (MRI)/computed tomography (CT) scan has been
             performed, there must be no evidence of any progressive abnormality or any lesion
             likely to be associated with partial-onset seizures

          -  Subject has been maintained on a stable dose regimen of 1 to 2 non-benzodiazepine
             marketed Anti-epileptic drugs (AEDs) OR 1 to 3 AEDs (with at least 1 AED identified
             as a benzodiazepine) for at least 28 days prior to Visit 1 with or without additional
             concurrent stable Vagus nerve stimulation (VNS)

          -  Subjects are required to have had an electroencephalogram (EEG) report consistent
             with IGE (eg, generalized ≥ 3Hz epileptiform discharges and a normal EEG background)
             confirmed by a Central Reviewer

        Exclusion Criteria:

          -  History of partial onset seizures or EEG findings indicating partial onset seizures

          -  Symptomatic generalized epilepsy, e.g. Lennox-Gastaut Syndrome

          -  Lifetime history of suicide attempt, or suicidal ideation in past 6 months

          -  Women of child bearing potential must practice contraception according to protocol
             requirements

          -  Regular use of neuroleptics, narcotics, monoamine oxidase (MOA) inhibitors,
             barbiturates (for indication other than epilepsy) within 28 days prior to Visit 1

          -  Use of Felbamate or Vigabatrin within last 6 months

          -  Subject is on a ketogenic diet
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trials Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB BIOSCIENCES, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>+1 877 822 9493</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Sp0982 28</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 005</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 008</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 031</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 036</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 003</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 011</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 002</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 001</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 019</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 042</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 015</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 021</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 041</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 007</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 010</name>
      <address>
        <city>Waldorf</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 004</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 025</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 014</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 044</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 039</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 034</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 027</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 023</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 201</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 200</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 203</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 500</name>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 554</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 550</name>
      <address>
        <city>Ostrava-Poruba</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 553</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 552</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 254</name>
      <address>
        <city>Anger Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 252</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 250</name>
      <address>
        <city>Rennes Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 305</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 300</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 309</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 303</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 304</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 302</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 301</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 306</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 600</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 601</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 901</name>
      <address>
        <city>Nigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 942</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 940</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 941</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 657</name>
      <address>
        <city>Czestoc Howa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 655</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 658</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 651</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 652</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 653</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 654</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 660</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 650</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 702</name>
      <address>
        <city>Campulung-Muscel</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 703</name>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 751</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 752</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 755</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 821</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 820</name>
      <address>
        <city>Dolni Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 823</name>
      <address>
        <city>Hlohovec</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 822</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 402</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sp0982 403</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 2, 2015</lastchanged_date>
  <firstreceived_date>March 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lacosamide</keyword>
  <keyword>Vimpat</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Children</keyword>
  <keyword>Primary Generalized Tonic Clonic seizures</keyword>
  <keyword>Idiopathic Generalized Epilepsy</keyword>
  <keyword>Adults</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Generalized</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
